Cargando…
Balancing the benefits and harms of oral anticoagulation in non-valvular atrial fibrillation
Non-valvular atrial fibrillation is becoming more common in Australia and globally The direct oral anticoagulants apixaban, dabigatran and rivaroxaban offer an improved safety profile over warfarin Patient preferences are important and shared decision-making supports better adherence to treatment
Autor principal: | Lindley, Richard I |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
NPS MedicineWise
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8075749/ https://www.ncbi.nlm.nih.gov/pubmed/33911332 http://dx.doi.org/10.18773/austprescr.2021.002 |
Ejemplares similares
-
Novel oral Anticoagulants in Non-Valvular Atrial Fibrillation
por: da Silva, Rose M.F.L.
Publicado: (2014) -
Prescribers’ perceptions of benefits and limitations of direct acting oral anticoagulants in non-valvular atrial fibrillation
por: Generalova, Daria, et al.
Publicado: (2020) -
Newer Anticoagulants for Non-Valvular Atrial Fibrillation
por: Harburger, Joseph M., et al.
Publicado: (2012) -
Non-persistence to Oral Anticoagulation Treatment in Patients with Non-valvular Atrial Fibrillation in the USA
por: Dhamane, Amol D, et al.
Publicado: (2021) -
Trials of Novel Oral Anticoagulants for Stroke Prevention In Patients with Non-valvular Atrial Fibrillation
por: Halperin, Jonathan L, et al.
Publicado: (2014)